Search Results

Stuart Maudsley on how an aging physiological context affects #GPCR signaling #drgpcr.

Terry's Corner : Stop Chasing Affinity and Start Reading the System In this week’s cornerstone Terry’ Lauren Slosky, Stuart Maudsley and Yamina Berchiche invite your insights for Volume II.

Stuart Maudsley, Nicole Perry-Hauser, Lauren Slosky, Cesare Orlandi, and Simone Prömel. GPCR University Save the date for our upcoming workshop starting May 9th, 2024, featuring Dr.

Start learning here ➤ Terry’s Corner — Early Safety Assays For Better GPCR Drug Discovery Decisions Too

But when the science starts to drift, teams often discover something uncomfortable. When they do not, it starts to fail quietly. The team is talented, but momentum starts leaking. 👉 Early-stage biotech hiring fails at this point, What Survival Traits Look Like in Real Biotech Work 👉 When founders start paying attention, they realize They start asking whether that person can still be effective when the ground shifts under their feet.

It means a commitment to continuous improvement — starting with the highest-friction gaps and working

September 2022 To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started

In reality, something more subtle starts to shift. 👉 Decision-making changes. Plans that once felt flexible start to feel constrained. Roadmaps stop being tools for choice and start becoming tools for justification. Strategic takeaway 👉 For biotech founders , financial failure rarely starts with an empty bank account It starts when financial control fades without being noticed . 👉 The key shift is not better reporting

doesn’t immediately tell them who it’s for, why it matters, and what makes it different, then they start They have to guess why it matters, what the application is, and whether it fits. ✅ Start with relevance People start leaning in. You stop explaining. People start connecting the dots for you. 👉 This is what clarity creates. Start refining your message. Ready to Break Your Bottlenecks?

struggling to predict structures from scratch, Alessandro and others could now use AI-generated models as starting “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery

Asking Better Questions in Science JB’s story makes one thing clear: asking better questions in science starts It starts by noticing what grabs your attention, what sparks those quiet “aha” moments during a lecture is the practical side of asking better questions in science: not the wording, but the willingness to start collaboration with David Hodson, every major leap—from early ligand design to GPCR visualization tools—started

Yet over time, alignment fades, and decisions start to feel disconnected. 👉 Many founders ask why biotech startups fail  not after a collapse, but when the company starts to feel harder to run without a clear decisions The turning point for many biotech startups comes when strategy stops being a document and starts Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent trusts execution because work is clearly tied to strategic intent. ✅ The company stops reacting and starts

When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. When Everything Is Strategic, Nothing Is Decisive 👉 Strategic overload starts with reasonable decisions From the outside, investors start to ask subtle questions. What is the real bet? Yet the hardest strategic decisions are rarely about starting something new. diluted commitment. 👉 Biotech fundraising reflects the structure of your strategy long before you start

Where Biotech Misalignment Starts 👉 Most misalignment doesn’t start with conflict. It starts with silence. You assume your CSO knows where you’re headed. Your BD person starts framing it for a niche diagnostic use. The board expects an IND package. Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

Starting From Zero: Growing With a Mentor When Alessandro joined Prof. At the start it was difficult, because you see all these projects and you think, ah, I don’t know… but

Drug-Like Properties: The Real Starting Point PK does not begin at dosing—it begins with physicochemical affinity and solubility limits routinely sabotage otherwise strong ligands Effective PK optimization starts with realistic starting points Early property mapping accelerates the design–test–learn cycle Drug discovery is faster when chemistry starts aligned with biology, not fighting it.

consistency: Can you show that your process will be scalable, repeatable, and GMP-compliant from the start Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start They start by asking: What would FDA approval actually require from us, and what decisions need to reflect Instead of collecting interesting data, you start collecting strategic evidence . tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

Watch Episode #177 Some scientific breakthroughs don’t start with a grant or a perfectly architected They start with a chance email, an unexpected visitor at the door, or the moment a team realizes the Their collaboration didn’t start as a big strategic play. It started with curiosity, openness, and the humility to admit that better answers required better tools

Rather than starting with a molecular hypothesis, Serafini’s team noticed that hamsters infected with By starting with phenotype-first studies , Serafini’s approach offers a translational lens more tightly

New initiatives start. Additional questions are explored. Prevents Drift Before It Becomes Failure Preventing this form of biotech startup failure  does not start It starts with a leadership shift. ✅ Founders must stop evaluating decisions individually and start managing or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

. ✅ Founders start adapting their message in real time , trying to meet expectations instead of setting Instead of starting from depth, it starts from relevance. better wording . 👉 Once positioning is decided, conversations stop revolving around explanation and start or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

“There was this very interesting phenotype the lab found where, as a mouse was starting to enter what we consider the chronic pain range, the mice that were constitutively RGS4 knocked out started recovering

Teams start planning around delays BD and investor messaging drifts Timelines become aspirational rather “we hope next year is better” → to “our cadence ensures it will be.” ✅ If you want a stronger 2025, start tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts interesting but unready.” 3️⃣ Internal Alignment Frays When “the science” drives everything, different teams start tradeoffs, or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start

Some breakthroughs don’t start with a grant or a roadmap — they start with a question no one expects It was the start of a scientific partnership with the potential to shift how GPCRs could be visualized What started as one molecule request is now a platform vision — a future where any GPCR could be illuminated

years of hard-won insight distilled into accessible, high-impact content designed for learners just starting

. 👉 Start your journey with Terry’s foundational series Unlock "Unique Role of Pharmacology" now

They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before Decisions stop being evaluated based on long-term leverage and start being filtered through a single What helps the raise starts to matter more than what strengthens the company. 👉 In practice, biotech Scientific nuance starts to feel inconvenient. or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

on both sides of the biotech fundraising table Why biotech fundraising breaks before diligence even starts 👉 This is where intellectual property gaps start to matter. the IP does not map cleanly to how the company plans to generate returns, the fundraising narrative starts tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

Some breakthroughs don’t start with a hypothesis. They start with a sentence that freezes the room. talk about the emotional side of discovery — the instant where the experiment stops being data and starts